

# Urgent Field Safety Notice

## SBN-CPS-2019-010



CPS / Coagulation

Version 2

Oct-2019

## cobas t 511/ t 711: Lifted cuvettes

<b>Product Name</b>	<b>cobas t 511 coagulation analyzer</b> <b>cobas t 711 coagulation analyzer</b> Cuvette <b>COBAS INTEGRA®</b>
<b>System</b>	<b>cobas t 511/ t 711</b>
<b>GMMI / Part No</b>	06356460001
<b>Device Identifier</b>	06355790001 21043862001
<b>Production Identifier (Product name/Product code)</b>	<b>Affected are all cobas t 511 and t 711 coagulation analyzer serial numbers</b> <b>Affected cuvette lots: Refer to attached lot number list.</b>
<b>SW Version</b>	All
<b>Type of Action</b>	Field Safety Corrective Action

Dear Valued Customer,

Roche Diagnostics regrets to inform you of reported cases affecting the **cobas t 511** and **cobas t 711** coagulation analyzers.

### Description of Situation

This FSN is relevant only for **cobas t 711** and **cobas t 511** coagulation analyzers already installed at customer sites, or in case these analyzers will be installed prior to a corrective action being fully implemented.

In the previous version of this FSN we informed that the affected lots of cuvettes (Cuvette **COBAS INTEGRA®**) may be slightly elevated in the incubator block of the **cobas t 711** and **cobas t 511** coagulation analyzer.

This is due to the dimensions of the cuvette versus the size of the incubator block hole.

Following further extensive testing, additional affected lot numbers have been identified as not being suitable for use on **cobas t 511/ 711** coagulation analyzers.

In the worst case, the cuvettes are not seated properly and remain slightly elevated in the incubator block during measurement.

This can result in unjustified Clot.E or NoClot Flags.

Furthermore, the occurrence of lifted cuvettes may directly influence results for HIL, AT, D-Dimer, Derived Fibrinogen, Anti-Xa and Free Protein S tests.

The impact of this will differ depending on where it occurred, either the cuvette blank position or a measurement position.

The following scenarios may be possible:

## Unjustified NoClot or Clot.E Flag

Results that under normal conditions yield an unflagged result may become flagged with NoClot or Clot.E.

The clotting curve should be checked in order to determine if a cuvette was lifted.

This can be detected if the curve starts in the negative absorbance area (see example below).




Figure 1: Example of negative absorbance area

Whether the sample is flagged as Clot.E or a NoClot depends on the individual sample and cannot be generally stated.

The following assays can be affected in this case:

- aPTT, aPTT Screen, aPTT Lupus
- PT Rec (applications A, B, C)
- Fibrinogen
- TT

## Direct result Influence

A direct result influence on the following assays is possible, deviations of more than 30% might occur:

- AT
- D-Dimer
- Derived Fibrinogen
- Anti-Xa
- Free Protein S

The result influence can impact patient results, QC as well as calibration measurements.

In the latter case, replicate deviations are observed (Dup.E).

## Influence on flags >I.H >I.I >I.L

The issue can lead either to a missing flag or to a wrongly flagged result.

*Note: Cuvette **COBAS INTEGRA**® is also used on **COBAS INTEGRA**® systems. **COBAS INTEGRA**® is not affected by this issue.*

# cobas t 511/ t 711: Lifted cuvettes



## Actions taken by Roche Diagnostics

### Correction:

#### Production of new cuvettes:

Only a small number of molding tools for cuvette production are affected.

These have been identified and affected molding tools have been blocked for production. Please refer to the list attached for further details.

#### Stock material:

Following further extensive testing, additional affected lot numbers have been identified as not being suitable for use on **cobas t 511/ 711** coagulation analyzers. Global Operations have subsequently performed a supply assessment to understand which countries have received these newly identified affected lots.

Affected cuvette lots have been blocked for countries with **cobas t 511** and **cobas t 711** coagulation analyzer installations and are therefore no longer being delivered.

Uninterrupted supply of affected lots continues to countries which do not have such installations in order to maintain continuous supply for **COBAS INTEGRA®** customers.

The process for monitoring deliveries continues to prevent deliveries of cuvettes not suitable for use on **cobas t 511** and **cobas t 711** coagulation analyzer in case a country will commence installations of the **cobas t 511** and **cobas t 711** coagulation analyzer.

Please refer to the updated list of affected lots attached to the FSN-CPS-2019-010 version 2.

### **Corrective Action:**

Long term, adaption of the design to align the tolerances between cuvette and incubator block is planned.

## Actions to be taken by the customer/user

**Please note:** **COBAS INTEGRA®** customers are not affected by this issue.

Please do not use the affected lot numbers of cuvettes on the **cobas t 511** and **cobas t 711** coagulation analyzer.

There are three possible actions:

- Use unaffected lots on **cobas t 511/t711**
- Usage of affected lot numbers for a **COBAS INTEGRA®** installation.
- Return the affected material to the affiliate if you have no **COBAS INTEGRA®** instrument

The lot number can be found on the label of the box, and also on each bag. Please refer to the updated list of affected lots attached to the FSN-CPS-2019-010 version 2.

# cobas t 511/ t 711: Lifted cuvettes




Figure 2: Label on box




Figure 3: Bag Label

Where stock of the Cuvette COBAS INTEGRA® is returned, replacement will be arranged by your local Roche representative

## Communication of this Field Safety Notice (if appropriate)

This notice must be passed on to all those who need to be aware within your organization where the devices have been distributed/supplied. (If appropriate).

Please transfer this notice to other organizations/individuals on which this action has an impact.

Please maintain awareness of this notice and resulting action for an appropriate period to ensure the effectiveness of the corrective action.

**The following statement is mandatory in FSNs for EEA countries but is not required for the rest of the World:**

*Include if applicable:* The undersigned confirms that this notice has been notified to the appropriate Regulatory Agency.

We apologize for any inconvenience this may cause and hope for your understanding and your support.

<closing salutations>,

### Contact Details

*To be completed locally:*

Name

Title

Company Name

Address

Tel. +xx-xxx-xxxx xxxx

Email name@roche.com